A newly described clinical strategy from Texas Children's Hospital and Baylor College of Medicine aims to shorten the diagnostic delay for biliary atresia (BA), a rare but aggressive liver disease in infants that can lead to irreversible liver injury if not treated within the first 30–45 days of life. The approach, published March 16, 2026, in World Journal of Pediatric Surgery (DOI: 10.1136/wjps-2025-001142), pairs direct or conjugated bilirubin (DB/Bc) measurements with a feeding abdominal ultrasound exam to give clinicians clearer signals when time is critical.
Biliary atresia, thought to begin before birth when extrahepatic bile ducts do not form properly, leads to bile buildup and progressive liver damage. The current standard of care, Kasai portoenterostomy (KP), offers the best chance of delaying or avoiding liver transplantation when performed before 30–45 days of age. However, many infants are diagnosed beyond 60 days due to subtle early signs—jaundice that mimics common newborn conditions and pale stools that may not appear immediately. The review highlights that DB/Bc levels can be elevated in the first 24–48 hours of life in infants with BA, even before clear clinical signs or other liver injury markers emerge.
The proposed pathway involves two practical steps. First, DB/Bc is measured in the newborn nursery and during early outpatient visits. Primary care providers are guided to test at 2–4 weeks when infants have persistent jaundice, pale stools, or a previous high DB/Bc result, consistent with American Academy of Pediatrics (AAP) guidance. Second, for infants with elevated DB/Bc, a feeding abdominal ultrasound is performed—the infant feeds before or during imaging, making the duct at the hilum (DaH) easier to visualize without requiring fasting. The exam also measures maximum echogenicity (MxE) near the right portal vein. An MxE greater than 4.0 mm or an absent DaH raises concern for BA and may prompt definitive evaluation, while other findings support continued outpatient assessment.
For leaders in healthcare and business, the implications are significant. Universal newborn DB/Bc screening could reduce diagnostic delays and address disparities by identifying risk before visual signs are missed or misread, potentially lowering long-term healthcare costs associated with liver transplantation. The feeding ultrasound approach also reduces the burden on families and healthcare systems by avoiding fasting and potentially reducing reliance on invasive tests requiring anesthesia. The authors emphasize that the strategy is designed to make early evaluation actionable for the full care team—from nursery providers and PCPs to radiologists, hepatologists, and surgeons—without replacing specialists' judgment.
The pathway builds on evidence from Texas Children's Hospital and collaborators at Stanford University School of Medicine. It was supported by funding from the NIH National Institute of Diabetes and Digestive and Kidney Diseases, the American Association for the Study of Liver Diseases, the American Liver Foundation, and Biliary Atresia Research and Education, Inc. The authors hope that sharing the pathway will encourage feedback and adaptation in other practice settings. Future studies will need to evaluate implementation, cost-effectiveness, and performance across multiple centers and healthcare systems.
